1. Home
  2. News
  3. Arovella Therapeutics Limited
  4. Arovella licences novel monoclonal antibody from MD Anderson
More Arovella Therapeutics Limited news
Arovella Therapeutics LimitedASX: ALA

Arovella licences novel monoclonal antibody from MD Anderson

Dec 12, 2021 at 10:49 PM EST · Issued by Arovella Therapeutics Limited

Filed with ASX · Dec 12, 2021 at 10:49 PM EST · 32 pages · English

On 6ix: 6ix.com/news/arovella-licences-novel-monoclonal-antibody-from-md-anderson

Arovella Therapeutics Limited on 6ix

In the deck

  • Arovella Therapeutics — Shareholder Meeting (December 2021)17 slidesDec 16, 2021

Earlier from Arovella Therapeutics

  • Chile Ministry of Health Approval Granted for ZolpiMistOct 20, 2021
  • GM presentationOct 13, 2021
  • Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SABAug 25, 2021
  • SUDA signs Licence and Distribution Agreement with STADAAug 24, 2021
  • ZolpiMist UpdateAug 23, 2021

Later from Arovella Therapeutics

  • AGM FY21 PresentationDec 15, 2021
  • Arovella Completes $4.57M Placement & Launches $1.5M SPPJan 23, 2022
  • SPP Offer BookletJan 23, 2022
  • Investor PresentationJan 31, 2022
  • Arovella SPP Closed early over subscribedFeb 21, 2022
All Arovella Therapeutics news releases↗

Follow Arovella Therapeutics into a list and get an email when it puts out news.

Follow Arovella Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer